NKTR - Nektar Therapeutics logo

Nektar Therapeutics

NKTR

Nektar Therapeutics develops immunotherapy medicines to treat autoimmune disorders, inflammatory diseases, and various cancers. Its pipeline includes treatments for ulcerative colitis, vitiligo, and solid tumors, leveraging proprietary drug development technologies.

โš•๏ธ Healthcare NASDAQ Listed 1994 $ USD
$1,000 invested 30 years ago โ†’$317today

Score Overview

1 Year
Score
Net Growth-8.03%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-5.52%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.4
Net Growth66.16%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-48.79%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-15.46%
Net Trend50%
Net Income Consistency
Rev Growth-68.46%
Rev Trend40%
Revenue Consistency
20 Years
Score2.4
Net Growth-14.54%
Net Trend45%
Net Income Consistency
Rev Growth-76.03%
Rev Trend50%
Revenue Consistency
30 Years
Score
Net Growth-15x
Net Trend43%
Net Income Consistency
Rev Growth7x
Rev Trend67%
Revenue Consistency
All Time
Score
Net Growth-31x
Net Trend41%
Net Income Consistency
Rev Growth30x
Rev Trend69%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Nektar Therapeutics has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • NKTR

2005: 85.3% ยท 2021: 97.6% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 35.91โ€”
1 Year2025-11-17
$ 59.58-39.73%
5 Years2021-11-17
$ 192.75-81.37%
10 Years2016-11-17
$ 209.55-82.86%
20 Years2006-11-17
$ 242.85-85.21%
30 Years1996-11-15
$ 113.44-68.34%
All Time1994-05-03
$ 56.25-36.16%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 52M-$ 177M$ 614M
2025$ 55M-$ 164M$ 245M
2024$ 98M-$ 118M$ 255M
2023$ 90M-$ 276M$ 303M
2022$ 92M-$ 368M$ 504M
2021$ 101M-$ 523M$ 733M
2020$ 152M-$ 444M$ 1.06B
2019$ 114M-$ 440M$ 1.32B
2018$ 1.19B$ 681M$ 1.33B
2017$ 307M-$ 96M$ 296M
2016$ 165M-$ 153M$ 389M
2015$ 230M-$ 81M$ 308M
2014$ 200M-$ 53M$ 237M
2013$ 148M-$ 162M$ 237M
2012$ 81M-$ 171M$ 277M
2011$ 71M-$ 133M$ 241M
2010$ 159M-$ 37M$ 315M
2009$ 71M-$ 102M$ 396M
2008$ 90M-$ 34M$ 378M
2007$ 273M-$ 32M$ 482M
2006$ 217M-$ 154M$ 458M
2005$ 126M-$ 185M$ 476M
2004$ 114M-$ 101M$ 418M
2003$ 106M-$ 46M$ 285M
2002$ 94M-$ 107M$ 293M
2001$ 77M-$ 250M$ 344M
2000$ 51M-$ 97M$ 484M
1999$ 41M-$ 38M$ 138M
1998$ 21M-$ 18M$ 82M
1997$ 16M-$ 9M$ 100M
1996$ 6M-$ 10M$ 18M
1995$ 3M-$ 7M$ 3M
IPO1994$ 1M-$ 5M$ 10M
NKTR - Nektar Therapeutics logo

Nektar Therapeutics fundamental performance

Between 2020 and 2025, revenue declined from $ 152M to $ 55M and net income went from -$ 444M to -$ 164M. Revenue increased in 1 of those 5 years; net income in 3.

Across Nektar Therapeutics's full reported history, from 1994 to 2025, revenue grew from $ 1M to $ 55M and net income went from -$ 5M to -$ 164M. Revenue increased in 69% of the years measured; net income in 41%.

Nektar Therapeutics currently holds a 20-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.

Membership

Continue NKTRโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies